LLerena A - Search Results

1

Pharmacogenetics: ethnicity, treatment and health in Latin American populations.

Sosa-Macías M, Fricke-Galindo I, Fariñas H, Monterde L, Ruiz-Cruz ED, Molina-Guarneros J, Tarazona-Santos E, Rodrigues-Soares F, Galaviz-Hernández C, Peñas-Lledó E, Moya G, Lara-Riegos J, Terán E, Hernández I, Ramírez-Roa R, Altamirano-Tinoco C, López-López M, García-Ortiz JE, LLerena A. Sosa-Macías M, et al. Among authors: llerena a. Pharmacogenomics. 2023 Jun;24(9):489-492. doi: 10.2217/pgs-2023-0098. Epub 2023 Aug 2. Pharmacogenomics. 2023. PMID: 37529900

2

Schizophrenia and tobacco smoking in a Spanish psychiatric hospital.

LLerena A, de la Rubia A, Peñas-Lledó EM, Diaz FJ, de Leon J. LLerena A, et al. Schizophr Res. 2003 Apr 1;60(2-3):313-7. doi: 10.1016/s0920-9964(02)00508-x. Schizophr Res. 2003. PMID: 12591592

3

Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism.

Dorado P, Berecz R, Peñas-Lledó EM, Llerena A. Dorado P, et al. Among authors: llerena a. Expert Opin Drug Metab Toxicol. 2007 Feb;3(1):9-19. doi: 10.1517/17425255.3.1.9. Expert Opin Drug Metab Toxicol. 2007. PMID: 17269891 Review.

4

Association between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs.

Peñas-Lledó EM, Dorado P, Cáceres MC, de la Rubia A, Llerena A. Peñas-Lledó EM, et al. Among authors: llerena a. Clin Chem Lab Med. 2007;45(7):835-8. doi: 10.1515/CCLM.2007.181. Clin Chem Lab Med. 2007. PMID: 17617023

5

Increased use of second generation antipsychotic drugs in primary care: potential relevance for hospitalizations in schizophrenia patients.

Cáceres MC, Peñas-Lledó EM, de la Rubia A, Llerena A. Cáceres MC, et al. Among authors: llerena a. Eur J Clin Pharmacol. 2008 Jan;64(1):73-6. doi: 10.1007/s00228-007-0386-1. Epub 2007 Oct 19. Eur J Clin Pharmacol. 2008. PMID: 17952424

6

CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits.

Dorado P, Peñas-Lledó EM, Llerena A. Dorado P, et al. Among authors: llerena a. Pharmacogenomics. 2007 Nov;8(11):1597-608. doi: 10.2217/14622416.8.11.1597. Pharmacogenomics. 2007. PMID: 18034624 Review.

7

Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers.

González I, Peñas-Lledó EM, Pérez B, Dorado P, Alvarez M, LLerena A. González I, et al. Among authors: llerena a. Pharmacogenomics. 2008 Jul;9(7):833-40. doi: 10.2217/14622416.9.7.833. Pharmacogenomics. 2008. PMID: 18597648

8

Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.

Llerena A, Dorado P, Peñas-Lledó EM. Llerena A, et al. Pharmacogenomics. 2009 Jan;10(1):17-28. doi: 10.2217/14622416.10.1.17. Pharmacogenomics. 2009. PMID: 19102711 Review.

9

Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients.

Dorado P, Peñas-LLedó EM, de la Rubia A, LLerena A. Dorado P, et al. Among authors: llerena a. Pharmacogenomics. 2009 Jul;10(7):1083-9. doi: 10.2217/pgs.09.57. Pharmacogenomics. 2009. PMID: 19604081

10

Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers.

Peñas-LLedó EM, Dorado P, Pacheco R, González I, LLerena A. Peñas-LLedó EM, et al. Among authors: llerena a. Pharmacogenomics. 2009 Jul;10(7):1111-20. doi: 10.2217/pgs.09.75. Pharmacogenomics. 2009. PMID: 19604084

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

252 results

Search Page

Filters